PALI — Palisade Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $7.30m
- $0.08m
Annual cashflow statement for Palisade Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.3 | -26.6 | -14.3 | -12.3 | -14.4 |
| Depreciation | |||||
| Non-Cash Items | 6.2 | 16.6 | -0.353 | 0.763 | 0.851 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.954 | -4.76 | 1.25 | 0.4 | 1.39 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -9.03 | -14.8 | -13.4 | -11.1 | -12.2 |
| Capital Expenditures | — | — | -0.01 | -0.004 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -0.054 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | — | -0.054 | -0.01 | -0.004 | 0 |
| Financing Cash Flow Items | — | -0.218 | -0.627 | -0.617 | -0.944 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.5 | 24.6 | 15.3 | 11.2 | 9.58 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.44 | 9.78 | 1.89 | 0.049 | -2.61 |